Stock report · Delisted · Nasdaq
Revance Therapeutics, Inc. (RVNC)
3.65USD Delisted Final close · Feb 5, 2025
RVNC no longer trades. Revance Therapeutics was delisted from the Nasdaq in February 2025.
All prices on this page are historical. The last trade was on February 5, 2025, at $3.65.
RVNC stock price history
Final trading statistics
- Final close
- $3.65
- Final trading day
- Feb 5, 2025
- Market cap at delisting
- $381.02M
- Shares outstanding
- 104.39M
- Final 52-week range
- $2.30 – $7.56
- Avg. volume (final 3 mo.)
- 3,209,000
- All-time high
- $40.78 · Nov 2015
- All-time low
- $2.34 · Jun 2024
- Return since IPO
- -86.4%
- Beta
- 0.95
- Book value / share
- −$1.55
- Price / book
- -2.35
About Revance Therapeutics, Inc.
Revance Therapeutics was a biotechnology company that developed, made and sold neuromodulators for aesthetic and medical uses in the U.S. and abroad. Its lead product, DAXXIFY (DaxibotulinumtoxinA-lanm) injection, treated glabellar lines and cervical dystonia. It had finished Phase II trials for upper facial lines, dynamic forehead lines and lateral canthal lines, and for adult upper limb spasticity and plantar fasciitis.
The company was developing a preclinical biosimilar to BOTOX (onabotulinumtoxinA) with Viatris. It also sold RHA dermal fillers for moderate to severe dynamic facial wrinkles and RHA Redensity for lines around the mouth.
Formerly Essentia Biosystems, it became Revance in April 2005. It was incorporated in 1999 and based in Nashville, Tennessee. As of February 6, 2025, it became a subsidiary of Crown Laboratories. Its shares were delisted from the Nasdaq in February 2025, with the final trade on February 5, 2025 at $3.65.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nashville, TN
- Employees
- 597
- IPO date
- February 6, 2014
- Delisted
- February 5, 2025
- SEC CIK
- 1479290
Revance Therapeutics financials before the delisting
The last 5 fiscal years Revance Therapeutics reported as a public company, fiscal year ending December.
RVNC revenue and net income
RVNC earnings per share
RVNC annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $234.04M | −$324.0M | −$3.79 |
| FY2022 | $132.56M | −$356.4M | −$3.94 |
| FY2021 | $77.80M | −$286.8M | −$4.18 |
| FY2020 | $15.32M | −$282.1M | −$4.83 |
| FY2019 | $413.0K | −$156.2M | −$3.66 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Revance Therapeutics stock FAQ
What happened to Revance Therapeutics stock?
Revance Therapeutics was delisted from the Nasdaq in February 2025. The final close was $3.65 on February 5, 2025.
Can I still buy RVNC stock?
No. RVNC is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on February 5, 2025.
What was the last price of RVNC?
RVNC last closed at $3.65 on February 5, 2025, which valued the company at about $381.02M.
How did Revance Therapeutics do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Revance Therapeutics reported revenue of $234.04M and net income of −$324.0M.
When did Revance Therapeutics go public?
Revance Therapeutics shares started trading on February 6, 2014.
RVNC no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.